Document Detail

What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents?
MedLine Citation:
PMID:  8864638     Owner:  NLM     Status:  MEDLINE    
Since the first publication of the University Group Diabetes Programme in 1970 the possible deleterious cardiovascular effects of certain hypoglycaemic sulphonylurea products has been well known. In contrast, international knowledge of the advantageous cardiovascular effects of certain sulphonylurea compounds became available recently. Glibenclamide decreases the incidence of fatal myocardial infarction and the development of ventricular fibrillation in patients suffering from acute myocardial infarction. It also lowers the incidence of ventricular ectopic beats in digitalized patients compared with patients treated with other investigated sulphonylurea compounds. The survival of patients treated with glibenclamide, insulin or diet alone is longer after the first attack of angina pectoris or after first acute myocardial infarction compared with those on other investigated sulphonylurea therapy. Glibenclamide decreases arrhythmogenesis during acute myocardial infarction in rats and strophanthin cardiotoxicity in rabbits. Arterial blood pressure and myocardial contractile force are not influenced by glibenclamide whereas these parameters are increased by other investigated sulphonylurea compounds. Consequently, deleterious cardiovascular effects of certain hypoglycaemic sulphonylurea drugs may contribute to the high cardiovascular mortality rate in diabetes mellitus, partly due to the effect on membrane channels and partly due to independent cardiac and extracardiac actions. Finally, recent observations suggest that glimepiride has a more advantageous cardiovascular effect than glibenclamide.
G Pogátsa
Related Documents :
10021498 - Effects of myosin isozyme shift on curvilinearity of the left ventricular end-systolic ...
23632968 - Loss of mir-29b following acute ischemic stroke contributes to neural cell death and in...
7585818 - Effects of opc-18790, a new positive inotropic agent, on energetics in the ischaemic ca...
152168 - Cardiac metabolsim: its contributions to alcoholic heart disease and myocardial failure.
20206898 - Validation and potential mechanisms of red cell distribution width as a prognostic mark...
18814218 - Complete versus incomplete revascularization in patients with multivessel disease under...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Diabetes research and clinical practice     Volume:  31 Suppl     ISSN:  0168-8227     ISO Abbreviation:  Diabetes Res. Clin. Pract.     Publication Date:  1996 Jul 
Date Detail:
Created Date:  1997-03-05     Completed Date:  1997-03-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8508335     Medline TA:  Diabetes Res Clin Pract     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  S27-31     Citation Subset:  IM    
National Institute of Cardiology, Research Department, Budapest, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Arrhythmias, Cardiac / drug therapy
Cardiovascular Diseases / complications,  drug therapy*
Diabetes Complications
Diabetes Mellitus / drug therapy*
Hypoglycemic Agents / therapeutic use*
Myocardial Ischemia / drug therapy
Sulfonylurea Compounds / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Sulfonylurea Compounds

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart.
Next Document:  Clinical profile of the novel sulphonylurea glimepiride.